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Obesity has been increasingly recognized as a risk factor for kidney disease and both
proteinuria and microalbuminuria have been associated with obesity. The actual prevalence of microalbuminuria and proteinuria in obese patients in the United States (US) has
not been clearly described in the literature. Furthermore, obesity is associated with risk
factors of kidney disease, such as diabetes and hypertension (HTN), and the prevalence
of proteinuria and albuminuria excluding these risk factors is uncertain. In this study, we
collected urine albumin/creatinine and urine protein/creatinine ratios on obese patients
undergoing bariatric surgery to determine the prevalence of albuminuria and proteinuria
in obese patients with and without associated diabetes and HTN. The study included
218 obese patients undergoing bariatric surgery at a New York City hospital. The mean
age was 42.1 ± 11.3 years. The mean body mass index (BMI) was 43.9 ± 8.1. Diabetes
(DM) was present in 25%. HTN was present in 47%. The prevalence of proteinuria
and albuminuria was 21% (95% CI: 15.8–27.1%) and 19.7% (95% CI: 14.2–26.2%)
respectively. Among those without DM but who had HTN, 22.6% (95% CI: 12.9–35)
had proteinuria and 17% (95% CI 8.4–30.9) had albuminuria. Of patients with neither
DM nor HTN, 13.3% (95% CI: 7.3–21.6) and 11% (95% CI: 5–17%) had proteinuria and
albuminuria, respectively. Diabetics had a significantly higher prevalence of proteinuria
and albuminuria than the non-diabetic groups. The non-diabetic groups did not differ significantly from each other in terms of prevalence of proteinuria and albuminuria. The BMI
for diabetics did not differ from non-diabetics. On multivariate analysis, only the presence
of diabetes was associated with proteinuria and albuminuria. BMI, age, and HTN were
not predictive. In conclusion, we found a relatively high prevalence of microalbuminuria
and proteinuria in an urban, US, obese population undergoing bariatric surgery. When
diabetics were excluded, there was a lower prevalence. Even patients who had neither
diabetes nor HTN, still, however, had much greater amounts than seen in the general US
population, likely reflecting an adverse effect of obesity itself on renal physiology.
Keywords: obesity, proteinuria prevalence, albuminuria prevalence, risk factors proteinuria, diabetes compli
cations, hypertension

INTRODUCTION
Obesity has been increasingly recognized as a risk factor for kidney disease (1, 2). Increased
body mass index (BMI) has been linked to glomerular hyperfiltration (3). Both proteinuria and
microalbuminuria have been associated with obesity (2). Pathologic changes in the kidney include
the development of focal segmental glomerulosclerosis and glomerulomegaly (4). Proteinuria has
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been shown to improve with a weight loss in a number of series
(1, 5). Increased BMI has been linked to a loss of renal function as
well as increased risk of end stage renal disease (1, 2). Despite all
of this evidence, the actual prevalence of microalbuminuria and
proteinuria in obese patients in the United States (US) has not
been clearly described in the literature. Furthermore, obesity is
associated with risk factors for the development of kidney disease,
such as diabetes and hypertension (HTN), and the prevalence of
proteinuria and albuminuria without these risk factors is not
certain. In this study, we collected urine albumin/creatinine and
urine protein/creatinine ratios on obese patients undergoing
bariatric surgery to determine the prevalence of albuminuria and
proteinuria in an obese population. We also wanted to evaluate
how the prevalence changed based on the presence or absence
of associated diabetes and HTN, in order to assess the relative
importance of these factors in obese patients, in contributing to
proteinuria and albuminuria.

variables and Chi-square test or Fisher’s exact test for categorical
variables. In the case of multiple comparisons, the significance
level was adjusted using the Bonferroni method. Two separate
multivariable logistic regression model were used to assess
the relationship between proposed factors and proteinuria or
albuminuria. Unless otherwise specified, a result was considered
statistically significant at the p < 0.05 level of significance. All
analyses were performed using SAS version 9.4 (SAS Institute,
Cary, NC, USA).

RESULTS
The study included 218 patients. Two hundred fourteen patients
had measurement of urine protein/creatinine and 183 patients
had urine albumin/creatinine measured. The mean age was
42.1 ± 11.3 years. The mean BMI was 43.9 ± 8.1. Diabetes was
present in 25%. HTN was present in 47% of all patients. The use
of ACE inhibitor/ARB was 26.2% overall in our population and
was present in 38.5 and 46.2% in patients with proteinuria and
albuminuria respectively. Baseline characteristics for all patients
and for each patient group are shown in Table 1. Diabetics were
slightly older and had more frequent use of ACEI/ARB than
the other groups. The BMI for diabetics did not differ from
non-diabetics.
The prevalence of proteinuria and albuminuria overall was
21% (95% CI: 15.8–27.1%) and 19.7% (95% CI: 14.2–26.2%),
respectively. Among patients with proteinuria, the median
amount was 223 mg (IQR: 183–357). Of those with albuminuria,
the median urine albumin was 83 mg (IQR: 55–203). Of patients
with albuminuria, 80.6% had microalbuminuria alone, and 19.4%
had macroalbuminuria. Of the patients with proteinuria, 40%
had DM as did 48.6% of the patients with albuminuria.
In analyzing the three patient groups, among DM patients
(with or without HTN), 33.3% (95% CI: 21.1–47.5) had proteinuria and 41.5% (95% CI: 26.3–57.9) had albuminuria. Among
those without DM but who had HTN, 22.6% (95% CI: 12.9–35)
had proteinuria and 17.7% (95% CI 8.4–30.9) had albuminuria.
Of patients with neither DM nor HTN, 13.3 (95% CI: 7.3–21.6%)
and 11.0% (95% CI: 4.9–18.9%) had proteinuria and albuminuria,
respectively. The percentages of proteinuria and albuminuria in
each patient group are shown in Table 2. Diabetics had a significantly higher prevalence of albuminuria than non-diabetics with
HTN (p = 0.012†) and non-diabetics with no HTN (p < 0.0001†).
Diabetics had a significantly higher prevalence of proteinuria
than non-diabetics with no HTN (p = 0.003†) but the increased
prevalence did not reach statistical significance when compared
with non-diabetics with HTN (0.20). The non-diabetic groups
did not differ significantly from each other in terms of prevalence
of proteinuria and albuminuria.

MATERIAL AND METHODS
Consecutive patients undergoing bariatric surgery at a single
hospital in New York City were recruited. Urine samples were
collected from each patient prior to surgery and sent for urine
albumin/creatinine and urine protein/creatinine ratios in order
to assess for both overall urine protein excretion as well as more
specifically albuminuria. Albuminuria was defined as an albumin
to creatinine ratio of more than 30 mg per gram of creatinine and
proteinuria as a protein to creatinine ratio of greater than 150 mg
per gram of creatinine. Patients with evidence of a urinary tract
infection or active urinary sediment were excluded. All patients
had BMI calculated preoperatively. Charts were reviewed for
associated diagnoses including diabetes and HTN as well as ACE
inhibitor or angiotensin receptor blocker (ARB) use.
For analysis of risk factors, patients were divided into three
groups: (1) diabetics with and without HTN (DM), (2) hypertensives without diabetes (HTN), and (3) those with neither. There
were too few diabetics without HTN to analyze separately. We
did not have data on other diagnoses such as glomerulonephritis
or lupus that could have contributed to renal disease, but patients
with evidence of active urinary sediment were excluded.

Statistical Analysis

Confidence intervals for proportions were obtained using the
Clopper–Pearson method. Continuous variables were compared
across the three patient groups using the Kruskal–Wallis or
one-way ANOVA test (as appropriate); categorical variables
were compared across the three groups using the Chi-square
or Fisher’s exact test (as appropriate). Post hoc tests were
accomplished using the Mann–Whitney or t-test for continuous
Table 1 | Baseline characteristics.

Age, mean ± SD
Body mass index, mean ± SD
ACEi/angiotensin receptor blocker (%)
Male (%)
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Overall (n = 218)

DM (n = 55)

Hypertension (HTN) only (n = 62)

No HTN, no DM (n = 101)

p-Value

42.1 ± 11.3
43.9 ± 8.1
57 (26.2%)
64 (29.4%)

47.1 ± 11.7
43.4 ± 10.1
30 (54.6%)
17 (30.9%)

45.5 ± 9.8
43.7 ± 7.7
27 (43.4%)
17 (27.4%)

37.2 ± 10.0
44.4 ± 7.3
0 (0%)
30 (29.7%)

<0.0001
0.21
<0.0001
0.91
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Table 2 | Prevalence of proteinuria and albuminuria in each patient group.

Proteinuria, n (%, CI)
Albuminuria, n (%, CI)

Overall (n = 218)

DM (n = 55)

Hypertension (HTN), no DM (n = 62)

No HTN, no DM (n = 101)

p-Value

45 (21.0%, 15.8–27.1)
36 (19.7%, 14.2–26.2)

18 (33.3%, 21.1–47.5)
17 (41.5%, 26.3–57.9)

14 (22.6%, 12.9–35)
9 (17.7%, 8.4–30.9)

13 (13.3%, 7.2–21.6)
10 (11.0%, 4.9–18.9)

0.01
0.0002

DM patients as a group had higher median amounts of protein
uria and albuminuria than the group without diabetes and without HTN. However, on post hoc analysis, there was not enough
evidence to conclude that they differed from the median amount
found in non-diabetics with HTN.
The BMI did not significantly differ between those with and
without proteinuria or albuminuria (p = 0.74 and p = 0.64,
respectively). Multivariable analysis showed that, among all
included factors (DM, age, HTN, and ACE inhibitor/ARB use),
DM was the only significant factor for proteinuria (p = 0.0001)
and albuminuria (p = 0.0001).

a recent report that “metabolically healthy obesity” without HTN
or evidence of metabolic syndrome is still associated with the
development of chronic kidney disease (10).
We found a higher prevalence of proteinuria and albuminuria
when compared with previous reports of renal disease in diabetics. For example, UKPDS reported 28% microalbuminuria and
7% proteinuria prevalence after 15 years of type 2 diabetes (11).
A report in type 1 diabetes found 34% microalbuminuria and
15% proteinuria after 18 years of median follow up (12). The
higher prevalence in our population, especially when compared with type 2 diabetics, could be due to the concomitant
obesity. Indeed, a published analysis of the Diabetes Control
and Complications Trial found that both waist circumference
and BMI were risk factors for the development of incident
microalbuminuria over 5.8 years in type 1 diabetics (13).
Unfortunately, in our population, we do not have information
of percentages on type 1 versus type 2 diabetes, the duration of
diabetes, nor the hemoglobin A1Cs of our patients in order to
further refine risks factors for diabetic kidney disease.
Approximately, a quarter of our patients were on ACEI or
ARB and it is likely that the prevalence of proteinuria and albuminuria as well as the absolute amounts of albumin and protein
excretion would be affected by the use of these medicines.
Indeed, it is likely that the extent of renal disease in our patients
is underestimated by our study. A study from Spain showed that
renal pathological changes, including mesangial matrix increase,
mesangial proliferation, podocyte, and glomerular hypertrophy,
could be found in a high percentage of very obese (BMI ≥ 40)
patients undergoing bariatric surgery, despite having no clinical
evidence of renal disease (14).
A limitation of our study is that albuminuria and proteinuria
were determined from a single morning urine sample. However,
studies have shown that morning random urine protein/
creatinine samples correlate well with 24-h urine protein and
may even be more predictive of renal disease progression than
24-hcollections (15). We also did not have information on uric
acid levels, triglycerides in order to assess other components
of the metabolic syndrome, which also may add to the risks for
kidney disease. We did not measure renin angiotensin aldosterone activation, leptin, or other adipokines which could have
a bearing on renal pathophysiology. Finally, we did not assess
for obesity pattern, peripheral or central, as was done in the
PREVEND study.
Also, it must be noted that our patients were specifically obese
patients who were undergoing bariatric surgery. These patients
likely differ in important ways from a non bariatric surgery obese
population. On the one hand, these patients were cleared for
major elective surgery, which presumably excluded patients at
highest cardiovascular risk. On the other hand, the fact that they
decided to undergo the surgery may reflect a concern for risk

DISCUSSION
Obesity has been increasingly recognized as a risk factor for
renal disease but the exact prevalence of albuminuria and
proteinuria, especially accounting for associated risk factors, is
not clear. Two studies from France were published in the 1990s
that did report on prevalence of albuminuria in overweight
and obese patients. One study found a prevalence of 7.1% of
microalbuminuria and 2.7% of macroalbuminuria in patients
without diabetes or HTN (6). The other study, which also did
not include diabetic patients but included hypertensives, found
no cases of proteinuria but did find a higher incidence of microalbuminuria in those with HTN (19 versus 9.7%) (7). Unlike
our study, both of these studies included non-obese, overweight
patients whose BMI was greater than 27. The third and by far
largest study addressing prevalence was the PREVEND study
from the Netherlands, published in 2003 (8). That study, which
excluded diabetics, found a prevalence of microalbuminuria of
21 or 13% depending on central or peripheral obesity patterns
(with central obesity having a higher incidence). Approximately
half of the patients in the study had HTN, but the prevalence
of albuminuria with and without HTN was not provided in the
obese population studied by PREVEND.
Our study is the first, to our knowledge, in an American
urban population. Our study, unlike previous studies, also only
included truly obese patients with BMI ≥ 30. Still, the prevalence
of albuminuria is remarkably similar to the findings from France
more than 20 years ago in an obese and overweight population
without diabetes or HTN (6, 7). This is also one of the first studies
on an obese population to focus on proteinuria in addition to
albuminuria in an obese population.
NHANES 3 data from 2002 showed that in the US population,
5.1% of people without diabetes or HTN had albuminuria and
0.3% had macroalbuminuria (9). Thus, even though it is clear
that concomitant diabetes or HTN greatly increases the risk of
albuminuria and proteinuria, it is evident from our study that
obesity itself more than doubled the prevalence of albuminuria
when compared with general population. This is consistent with
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factors such as concomitant DM and HTN and other complications of obesity that could impact renal disease.
In conclusion, we found a relatively high prevalence of
albuminuria and proteinuria in an urban, US, obese population
undergoing bariatric surgery. When diabetics were excluded,
there was a lower prevalence and the mean amounts of proteinuria and albuminuria were less. Non-diabetic obese patients
with HTN had more albuminuria and proteinuria than those
without HTN, but this did not reach statistical significance in
our population. Obese patients who had neither diabetes nor
HTN, in other words without another apparent cause of renal
disease, still had much greater amounts than seen in the general
United States population as described in the NHANES data.
This likely reflects an adverse effect of obesity itself on renal
physiology. Considering that albuminuria and proteinuria are
well recognized risk factors for progressive renal disease as well
as cardiovascular disease, this highlights one reason among
many for the crucial need to reverse the rising worldwide
obesity epidemic.
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